Press Releases

INCLINE VILLAGE, Nev. , Dec. 13, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of its

Will Pursue Monetization of its Assets and Optimal Means of Returning Proceeds to Shareholders; Will Cease Making Additional Strategic Acquisitions and Investments Board Authorizes Repurchase Program to Acquire up to $200 Million of Outstanding PDL Stock and Convertible Notes Conference Call at

INCLINE VILLAGE, Nev. , Dec. 3, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) congratulates Evofem Biosciences, Inc. ("Evofem") (NASDAQ: EVFM) on its recent achievement of two major regulatory and clinical milestones with its lead product candidate Amphora ®

Responds to Escalation of Engine Capital's Public Campaign INCLINE VILLAGE, Nev. , Nov. 14, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today issued the following statement in response to Engine Capital LP's ("Engine") escalation of its public campaign

Revenues of $44.2 million includes continued growth from LENSAR and strong contribution from royalty assets Conference call at 4:30 p.m. Eastern time today INCLINE VILLAGE, Nev. , Nov. 6, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for

INCLINE VILLAGE, Nev. , Oct. 30, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter 2019 financial results for the period ended September 30, 2019 , on Wednesday, November 6, 2019 , after market close.

INCLINE VILLAGE, Nev. , Oct. 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that Harold E. Selick , Ph.D., Chairman of the Board of Directors of PDL BioPharma , has sent the following letter to Engine Capital, LP .

  INCLINE VILLAGE, Nev. , Sept. 26, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019 ,

INCLINE VILLAGE, Nev. , Sept. 12, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate privately negotiated transactions to exchange approximately $86.1 million in aggregate principal amount of its 2.75% Convertible

INCLINE VILLAGE, Nev. , Sept. 11, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced that the Supreme Court of New York , County of New York , Commercial Division, issued its decision today in PDL's previously disclosed litigation related to defaults by

INCLINE VILLAGE, Nev. , Aug. 7, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2019 : Second Quarter and Recent Financial Highlights Generally Accepted Accounting Principles ("GAAP") net loss

INCLINE VILLAGE, Nev. , July 31, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its second quarter 2019 financial results for the period ended June 30, 2019 , on Wednesday, August 7, 2019 , after market close.

INCLINE VILLAGE, Nev. , June 25, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the resignation of Chief Financial Officer, Peter Garcia , who will be leaving the Company effective August 15, 2019 . He will continue in his role through the filing

INCLINE VILLAGE, Nev. , June 24, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that at its 2019 annual meeting of stockholders held June 20, 2019 , the Company's stockholders elected Natasha A. Hernday to the Company's Board of Directors.

- Strategic financing to advance the commercialization of Evofem's lead asset, Amphora® - SAN DIEGO and INCLINE VILLAGE, Nev. , June 10, 2019 /PRNewswire/ --  Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc.